SG Americas Securities LLC Has $220,000 Stake in argenx SE (NASDAQ:ARGX)

SG Americas Securities LLC increased its position in argenx SE (NASDAQ:ARGX) by 6.2% in the 4th quarter, Holdings Channel reports. The firm owned 358 shares of the company’s stock after buying an additional 21 shares during the quarter. SG Americas Securities LLC’s holdings in argenx were worth $220,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. Cromwell Holdings LLC lifted its holdings in shares of argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after acquiring an additional 66 shares during the period. GAMMA Investing LLC raised its position in argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after purchasing an additional 56 shares in the last quarter. Fulton Bank N.A. bought a new position in argenx during the fourth quarter worth about $226,000. Blue Trust Inc. boosted its holdings in argenx by 413.9% during the third quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after purchasing an additional 298 shares in the last quarter. Finally, Keudell Morrison Wealth Management bought a new stake in shares of argenx in the 3rd quarter valued at approximately $207,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ARGX. JPMorgan Chase & Co. raised their target price on argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. Robert W. Baird cut argenx from an “outperform” rating to a “neutral” rating and lifted their price objective for the company from $515.00 to $650.00 in a report on Friday, November 1st. Baird R W lowered shares of argenx from a “strong-buy” rating to a “hold” rating in a report on Friday, November 1st. Evercore ISI lifted their price target on shares of argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Finally, Deutsche Bank Aktiengesellschaft cut shares of argenx from a “hold” rating to a “sell” rating in a research note on Friday, January 17th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $658.39.

argenx Price Performance

Shares of NASDAQ:ARGX opened at $646.64 on Friday. The stock has a market cap of $39.29 billion, a price-to-earnings ratio of -734.82 and a beta of 0.58. The company has a 50 day moving average of $636.51 and a 200-day moving average of $574.93. argenx SE has a one year low of $349.86 and a one year high of $678.21.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.